Back
63
39
59
Also listed as
WUXAY
OTC
Day Range
$13.88
$15.00
52-Week Range
$7.34
$16.80
Volume
600
50D / 200D Avg
$14.12
/
$12.83
Prev Close
$13.88
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 4.4 | 0.4 |
| P/B | 0.7 | 2.9 |
| ROE % | 16.6 | 3.7 |
| Net Margin % | 24.1 | 3.8 |
| Rev Growth 5Y % | 24.1 | 10.0 |
| D/E | 0.1 | 0.2 |
Key Takeaways
Revenue grew 24.12% annually over 5 years — strong growth
ROE of 16.62% — decent returns on equity
Net margin of 24.08% shows strong profitability
Debt/Equity of 0.08 — conservative balance sheet
Generating 8.40B in free cash flow
P/E of 4.38 — trading at a low valuation
Growth
Revenue Growth (5Y)
24.12%
Revenue (1Y)-2.73%
Earnings (1Y)-1.63%
FCF Growth (3Y)259.46%
Quality
Return on Equity
16.62%
ROIC13.70%
Net Margin24.08%
Op. Margin29.51%
Safety
Debt / Equity
0.08
Current Ratio2.38
Interest Coverage53.60
Valuation
P/E Ratio
4.38
P/B Ratio0.71
EV/EBITDA2.40
Dividend Yield0.02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -2.73% | Revenue Growth (3Y) | -0.14% |
| Earnings Growth (1Y) | -1.63% | Earnings Growth (3Y) | 3.55% |
| Revenue Growth (5Y) | 24.12% | Earnings Growth (5Y) | 33.67% |
| Profitability | |||
| Revenue (TTM) | 39.24B | Net Income (TTM) | 9.45B |
| ROE | 16.62% | ROA | 11.76% |
| Gross Margin | 41.48% | Operating Margin | 29.51% |
| Net Margin | 24.08% | Free Cash Flow (TTM) | 8.40B |
| ROIC | 13.70% | FCF Growth (3Y) | 259.46% |
| Safety | |||
| Debt / Equity | 0.08 | Current Ratio | 2.38 |
| Interest Coverage | 53.60 | Dividend Yield | 0.02% |
| Valuation | |||
| P/E Ratio | 4.38 | P/B Ratio | 0.71 |
| P/S Ratio | 1.06 | PEG Ratio | 12.27 |
| EV/EBITDA | 2.40 | Dividend Yield | 0.02% |
| Market Cap | 41.41B | Enterprise Value | 27.84B |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 39.24B | 40.34B | 39.35B | 22.90B | 16.54B |
| Net Income | 9.45B | 9.61B | 8.81B | 5.10B | 2.96B |
| EPS (Diluted) | 3.26 | 3.24 | 2.82 | 1.73 | 1.05 |
| Gross Profit | 16.28B | 16.57B | 14.68B | 8.31B | 6.28B |
| Operating Income | 11.58B | 11.87B | 10.65B | 6.04B | 3.39B |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 80.33B | 73.67B | 64.69B | 55.13B | 46.29B |
| Total Liabilities | 21.24B | 18.15B | 17.76B | 16.37B | 13.57B |
| Shareholders' Equity | 58.63B | 55.12B | 46.59B | 38.49B | 32.49B |
| Total Debt | 4.75B | 5.45B | 5.87B | 4.28B | 4.29B |
| Cash & Equivalents | 18.32B | 13.76B | 7.99B | 8.24B | 10.24B |
| Current Assets | 38.69B | 30.42B | 24.00B | 21.99B | 23.06B |
| Current Liabilities | 16.23B | 14.76B | 14.50B | 12.98B | 7.92B |
Strategy Scores
This stock passed the criteria for 3 strategies
Score = fit strength (0–100)
Rank = position among all matches
#104 of 820
#239 of 658
#75 of 708
Recent Activity
Entered
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered
Contrarian Investing (David Dreman)
Mar 24, 2026
Entered
Defensive Investing (Benjamin Graham)
Mar 24, 2026